Showing 110 results
-
Media Release /Montreal, March 30th, 2026 – Novartis Pharmaceuticals Canada Inc. (“Novartis Canada”) is calling on Canadian early‑career oncology clinicians and researchers to submit abstracts for the 2026 Novartis…
-
Media Release /Novartis has a long-standing history in Canada, and is committed to delivering improved outcomes for millions of patients. In 2022, Novartis invested a total of $450 million in Canada.The office has…
-
Media Release /The draft recommendation for Kisqali® (ribociclib tablets) from Canada’s Drug Agency (CDA-AMC) supports public reimbursement for hormone receptor (HR)-positive, human epidermal growth factor receptor…
-
Webform /Novartis Canada is deeply committed to providing support to organizations that deliver real benefits to our communities and beyond. To this end, we are implementing new guiding principles to…
-
Media Release /Novartis Canada applauds the positive funding recommendations for Scemblix® (asciminib) for both newly diagnosed and previously treated patients with Philadelphia chromosome-positive chronic myeloid…
-
Media Release /Novartis applauds Ontario’s bold leadership in launching the FAST program, which accelerates access to breakthrough therapies like Scemblix® for patients living with cancer.Scemblix® (asciminib) was…
-
Media Release /Quebec has the highest rate of breast cancer in Canada.1 The Government of Quebec recently endorsed lowering the breast cancer screening age for women,2,3 reflecting the province’s commitment…
-
Media Release /The Novartis Health Equity Initiative continues to support projects tackling systemic health disparities and promoting equitable access to healthcare across Canada.To date, the initiative drew over…
